The DOI matches its Crossref record.
Crossover Comparison of Rizatriptan 5 mg and 10 mg Versus Sumatriptan 25 mg and 50 mg in Migraine
Abstract
Rizatriptan is a selective 5‐HT 1B/1D receptor agonist with rapid oral absorption and early onset of action in the acute treatment of migraine. This double‐blind, placebo‐controlled, crossover study compared rizatriptan 5 mg versus sumatriptan 25 mg, and rizatriptan 10 mg versus sumatriptan 50 mg. A total of 1329 patients were allocated to one of five groups for treatment of two attacks: rizatriptan 5 mg/sumatriptan 25 mg; sumatriptan 25 mg/rizatriptan 5 mg; rizatriptan 10 mg/sumatriptan 50 mg; sumatriptan 50 mg/rizatriptan 10 mg; placebo/placebo. For each attack, patients rated headache severity, presence of associated symptoms, and functional disability prior to dosing and at intervals through 4 hours thereafter. Patients also rated their satisfaction with medication. Rizatriptan 5 mg and 10 mg provided faster relief of headache pain and greater relief of migraine symptoms than the 25‐mg and 50‐mg doses of sumatriptan, respectively. The response to rizatriptan was better than sumatriptan on additional measures including functional disability and satisfaction with medication. All active treatments were highly effective compared to placebo and acted as early as 30 minutes after dosing. All active treatments were well‐tolerated and showed comparable safety profiles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
EFNS guideline on the drug treatment of migraine—revised report of an EFNS task force
Evers, S., Áfra, J., Frese, A., Goadsby, P. J., Linde, M., May, A., & Sándor, P. S. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02748.x · Cited by 892
Guidelines for Controlled Trials of Drugs in Migraine: Second Edition
International Headache Society Clinical Trials Subcommittee, Tfelt-Hansen, P., Block, G., Dahlöf, C., Diener, H.-C., Ferrari, M., Goadsby, P., Guidetti, V, Jones, B., Lipton, R., et al. (2000) · Cephalalgia · doi:10.1046/j.1468-2982.2000.00117.x · Cited by 698
Self-citationFerrari, M., Goadsby, P., Roon, K., & Lipton, R. (2002) · Cephalalgia · doi:10.1046/j.1468-2982.2002.00404.x · Cited by 605
Triptans in Migraine: A Comparative Review of Pharmacology, Pharmacokinetics and Efficacy
Tfelt-Hansen, P., De Vries, P., & Saxena, P. R. (2000) · Drugs · doi:10.2165/00003495-200060060-00003 · Cited by 529
Guidelines for controlled trials of drugs in migraine: Third edition. A guide for investigators
International Headache Society Clinical Trials Subcommittee members:, Tfelt-Hansen, P., Pascual, J., Ramadan, N., Dahlöf, C., D'Amico, D., Diener, H.-C., Hansen, J. M., Lanteri-Minet, M., Loder, E., et al. (2012) · Cephalalgia · doi:10.1177/0333102411417901 · Cited by 365
Metadata
- Authors
- Goldstein, J., Ryan, R., Jiang, K., Getson, A., Norman, B., Block, G. A., Lines, C., & Rizatriptan Protocol 046 Study Group
- Venue
- Headache: The Journal of Head and Face Pain
- Publisher
- Wiley
- Published
- 1998-11
- Volume
- 38
- Issue
- 10
- Pages
- 737-747
- ISSN
- 0017-8748 (ISSN-L)
- 1526-4610
- OpenAlex
- W2039623332
- Cited by
- 163
- References
- 0
- FWCI
- 13.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Crossover Comparison of Rizatriptan 5 mg and 10 mg Versus Sumatriptan 25 mg and 50 mg in Migraine. https://app.cochat.ai/papers/10.1046/j.1526-4610.1998.3810737.x
- The paper
- Goldstein, J., Ryan, R., Jiang, K., Getson, A., Norman, B., Block, G. A., Lines, C., & Rizatriptan Protocol 046 Study Group. (1998). Crossover Comparison of Rizatriptan 5 mg and 10 mg Versus Sumatriptan 25 mg and 50 mg in Migraine. Headache: The Journal of Head and Face Pain. https://doi.org/10.1046/j.1526-4610.1998.3810737.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.